Alex R. Thurman, Senior Vice President and Chief Financial Officer of Glaukos Corp (NASDAQ:GKOS), sold 14,800 shares of common stock on November 18, 2026, generating total proceeds of $3,553,763. The shares changed hands at prices ranging from $232.18 to $246.41 apiece. The transaction took place as the stock hovered near its 52-week high of $255.19, following a striking 138% return over the past year. Nonetheless, some analytical assessments indicate the stock may be overvalued at current levels.
The sale was conducted pursuant to a Rule 10b5-1 trading plan that Thurman adopted on August 18, 2026. This pre-arranged plan also governed the exercise of options scheduled to expire on March 15, 2027. On the same date, Thurman acquired 15,000 shares of common stock by exercising stock options at an exercise price of $45.71 per share, for a total cost of $685,650. That option exercise was likewise part of the pre-arranged Rule 10b5-1 plan.
After these transactions, Thurman's direct beneficial ownership in Glaukos Corp amounts to 43,906 shares of common stock. This figure includes 5,230 restricted stock units that have not yet vested or been delivered to him.
The company's outlook appears positive, with analyst sentiment reflecting upward revisions. According to available data, 11 analysts have revised their earnings estimates upward for the upcoming period. Additional detailed analysis and further proprietary insights are accessible through subscription platforms.
In other recent developments, Glaukos Corporation reported significant financial achievements for the third quarter of 2026. Total revenue reached $211 million, representing a 58% increase year-over-year and surpassing expectations from analysts at firms such as Piper Sandler and Needham. The revenue performance was highlighted by the strength of the company's Epioxa segment, which contributed to a positive turn in profitability. Glaukos management also raised its revenue guidance for 2026 by 13% and introduced a 2027 revenue outlook of approximately $1 billion, exceeding previous consensus estimates.
Several analyst firms have responded to these developments by raising their stock price targets for Glaukos. BTIG increased its target to $252, while H.C. Wainwright set theirs at $248, citing the strong third-quarter results. Piper Sandler and Needham also raised their targets to $240 and $251, respectively, both maintaining positive ratings on the stock. Mizuho, noting impressive U.S. Glaucoma and Corneal Health performance, raised its price target to $225. These updates reflect the analysts' positive outlook on Glaukos following its robust financial results.
The stock most recently closed at $237.31, down $0.79 or 0.33%, on volume of 15:59:59. In after-hours trading, the price remained unchanged at $237.31.